Lanadelumab

(Takhzyro-flyo)

Lanadelumab

Drug updated on 11/16/2023

Dosage FormInjection (subcutaneous: 300 mg/2 mL (150 mg/mL))
Drug ClassPlasma kallikrein inhibitor (monoclonal antibody)
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older.